Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Discovery Platform
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $2,000.0 million
Deal Type : Collaboration
Ribo Partners with Boehringer to Develop New Treatments for People with Liver Diseases
Details : The collaboration aims to develop novel treatments for NASH/MASH using Ribo's siRNA expertise and Boehringer's commitment to improving lives in cardiovascular, renal, and metabolic diseases.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 03, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Discovery Platform
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $2,000.0 million
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?